| Today’s Big NewsFeb 7, 2024 |
| By Annalee Armstrong Facing a full FDA clinical hold on a clutch of studies, Gilead is ending development of magrolimab in blood cancer after an “increased risk of death” was observed in a late-stage trial for the med. |
|
|
|
By Helen Floersh,Gabrielle Masson Amgen's obesity drug MariTide stimulates weight loss in animals and people without major side effects, new data from the company show. And unlike its competitors, it may only need to be taken once a month and perhaps not for life. |
By Max Bayer Gilead will not buy immunotherapy biotech Tizona Therapeutics, backing out of an option that the company paid $300 million for in 2020. |
Sponsored by ICON In this exclusive interview, ICON Biotech President Chris Smyth paints a picture of the operating environment facing biotechs in 2024. |
|
Since most new drugs fail because of ADME/Tox, you can add considerable value to your compound by preemptively demonstrating low risk data. Learn how to leverage your data to maximize value: Read More >> 
|
|
By Annalee Armstrong,Zoey Becker With supply strains not letting up in the growing injectable obesity med market, Lilly looks to carve out manufacturing early for its oral candidate. |
By James Waldron I-Mab’s plan to become a U.S.-focused biotech took a stride forward with the news that the company is divesting its China operations. |
By Max Bayer A new life science fund is emerging with over $300 million at hand and the leadership of two former investors from Apple Tree Partners. Scion Life Sciences is affiliated with healthcare private equity firm Petrichor, but the new fund is a standalone business. |
By James Waldron Jazz has returned to Redx Pharma’s well, this time paying $10 million upfront for a KRAS program that includes the much-hyped G12D space. |
By Nick Paul Taylor Arrowhead Pharmaceuticals is terminating development of a pair of pipeline prospects as part of a push to be more strategic about where it puts its dollars. With costs rising as programs enter late-stage trials, the RNA specialist plans to look “more vigorously” for partners and cull assets outside its areas of focus. |
By Angus Liu Despite reaching new heights in breast cancer, Eli Lilly’s Verzenio has been sent packing in prostate cancer. Meanwhile, the Indianapolis pharma has another phase 3 prostate cancer program in the works. |
By Andrea Park With the number of healthcare workers experiencing burnout at an all-time high, Ambience Healthcare is betting on artificial intelligence as a potential solution. |
By Fraiser Kansteiner While Japan’s Eisai had set the goal to reach 10,000 patients with Leqembi by the end of its 2024 fiscal year, which wraps up in March, only 2,000 patients in the U.S. were receiving the amyloid-busting antibody as of Jan. 26, Eisai explained in a third-quarter earnings presentation. |
By Heather Landi Amazon is eliminating a "few hundred roles" across One Medical and Amazon Pharmacy, the company confirmed Tuesday. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” Fierce’s Conor Hale interviews Peter Shen, the North American head of digital health at Siemens Healthineers, to explore what developers and regulators can do to ensure transparency in medical AI. He also dives into how the field could potentially benefit from a 21st-century update to the Hippocratic Oath. |
|
|---|
|
|
|
Stability and particle formation are key variables across the lifecycle. New instruments that improve measurement are transforming testing and becoming necessary. Download this essential reading now for biopharma companies that want to understand how particle detection is evolving and the value new technologies provide across the lifecycle. 
|
|
Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
